BioCryst®

BioCryst Pharmaceuticals stock generated USD 218.25 million in Q2 2026 revenue, up 33.6 percent year over year. JPMorgan lifted its target while keeping a neutral rating.

BioCryst Pharmaceuticals (NASDAQ:BCRX) is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief Executive Officer Charlie Gayer said at a Morgan Stanley e

On August 28, 2026, CNBC reported that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), now consistently profitable on the strength of its hereditary angioedema drug

BioCryst Pharmaceuticals (BCRX) has drawn fresh attention after recent trading left the share price at US$8.12, with the stock down over the past week and month but modestly higher year to date. Recent trading tells a mixed story for BioCryst Pharmaceutic

BioCryst Pharmaceuticals' Astria Therapeutics acquisition brings navenibart, a drug in Phase 3 testing for the rare disease hereditary angioedema. The injectable antibody has the potential to match the efficacy of the blockbuster Takeda Pharmaceutical dru